title: Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.
abstract: OBJECTIVE
  To study whether the effect of allopurinol on improvement of endothelial dysfunction in chronic heart failure (CHF) translates into improved exercise capacity and to examine whether allopurinol also improves B-type natriuretic peptide (BNP), the other important prognostic marker of CHF.
  
  
  METHODS
  Randomised, double blind, placebo controlled crossover trial.
  
  
  METHODS
  Teaching hospital.
  
  
  METHODS
  50 patients with CHF (New York Heart Association functional classes II and III) were recruited.
  
  
  METHODS
  50 patients with CHF were randomly assigned to three months' treatment with allopurinol (300 mg/day) or placebo. At two and three months into treatment, they underwent a modified Bruce exercise protocol and a six minute walk test. Blood was taken for BNP and haemoglobin analysis.
  
  
  RESULTS
  Neither exercise test was altered by allopurinol. However, plasma BNP concentrations fell significantly (p = 0.035) with allopurinol (11.9 pmol/l) versus placebo (14.4 pmol/l). Haemoglobin concentrations also fell highly significantly with allopurinol (p = 0.001).
  
  
  CONCLUSIONS
  An important negative finding is that despite high hopes for it, allopurinol had no effect on exercise capacity in CHF. On the other hand, allopurinol did reduce BNP, which is the best available surrogate marker for prognosis in CHF.
authors.affiliation: Division of Medicine & Therapeutics, Ninewells Hospital & Medical School, Dundee, UK.
authors.forename: A D
authors.initials: AD
authors.lastname: Gavin
authors.forename: A D
authors.initials: AD
authors.lastname: Struthers
mesh_terms: D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use*; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D017079:Exercise Tolerance / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
chemical_list: D015415:Biomarkers; D004791:Enzyme Inhibitors; D006454:Hemoglobins; D020097:Natriuretic Peptide, Brain; D000493:Allopurinol; D014969:Xanthine Oxidase